ACT is pleased to announce the following webinar hosted by the Scientific Liaison Coalition:
Title: Prediction Is Very Difficult, Especially If It Is About the Future: How Well Does Toxicology Testing Predict Clinical Outcomes?
Presenter: Dr. Thomas W. Jones
Date/Time: February 4, 2015, 11:00 AM–12:30 PM (ET) USA
On Wednesday, February 4, 2015, the Scientific Liaison Coalition (SLC) will host a webinar, “
Prediction Is Very Difficult, Especially If It Is About the Future: How Well Does Toxicology Testing Predict Clinical Outcomes?” presented by Dr. Thomas W. Jones. The webinar will be held from 11:00 AM to 12:30 PM (ET). SLC 2014-2015 Chair Mary Jeanne Kallman will host the webinar and Immediate Past Chair Kevin McDorman will serve as the moderator. You will need to
register for this webinar. Space is limited.
Dr. Jones notes in the abstract of this presentation that “….the debate around the future of nonclinical safety testing has been hampered by an inability to define the performance characteristics of the current nonclinical safety testing paradigm. This presentation will consider a quantitative framework with which nonclinical safety model performance can be assessed, highlight the data needed to enable such an approach, and discuss the implications of new model and technology applications in pharmaceutical R&D.”
Dr. Jones is the Chief Scientific Officer of Toxicology and Pathology, at Eli Lilly and Company. He is currently Past Chair of the Preclinical Safety Leadership Group within the International Consortium for Innovation and Quality in Pharmaceutical Development. He also serves as the nonclinical safety representative for the Development Special Emphasis Panel supporting the National Cancer Institute Experimental Therapeutics (NExT) Program.
The webinar only is available to members of the SLC participating societies and illustrates the mission of the SLC of “improving the ability of societies to partner with other domestic and international organizations that have objectives consistent with the goal of increasing the impact of the science of toxicology to improve public health” by:
• Strengthening partnerships among scientific- and health-based organizations to increase awareness of the impact of toxicology and related subjects on human health; and
• Functioning as a means to enhance cooperation among societies as equals with the goal of accomplishing tasks benefiting human health and disease prevention through joint and several shared activities.
In addition to the American College of Toxicology (ACT), participating societies in the SLC include the American Association for Cancer Research (AACR), American Academy of Clinical Toxicology (AACT), American College of Medical Toxicology (ACMT), The Endocrine Society (ENDO), Environmental Mutagenesis and Genomics Society (EMGS), International Society for the Study of Xenobiotics (ISSX), Safety Pharmacology Society (SPS), Society for Risk Analysis (SRA), Society of Environmental Toxicology and Chemistry (SETAC), Society of Toxicologic Pathology (STP), Society of Toxicology (SOT), and Teratology Society (Teratology).